KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Retained Earnings (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Retained Earnings readings, the most recent being -$1.6 billion for Q4 2025.

  • On a quarterly basis, Retained Earnings changed N/A to -$1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.6 billion, a N/A change, with the full-year FY2025 number at -$1.6 billion, changed N/A from a year prior.
  • Retained Earnings hit -$1.6 billion in Q4 2025 for Esperion Therapeutics, up from -$1.7 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$93000.0 in Q3 2022 to a low of -$1.7 billion in Q3 2025.
  • Median Retained Earnings over the past 5 years was -$1.3 billion (2022), compared with a mean of -$1.2 billion.
  • Biggest five-year swings in Retained Earnings: surged 99.99% in 2022 and later plummeted 532886.69% in 2023.
  • Esperion Therapeutics' Retained Earnings stood at -$1.1 billion in 2021, then fell by 21.12% to -$1.3 billion in 2022, then dropped by 4.61% to -$1.4 billion in 2023, then dropped by 12.7% to -$1.6 billion in 2024, then decreased by 2.79% to -$1.6 billion in 2025.
  • The last three reported values for Retained Earnings were -$1.6 billion (Q4 2025), -$1.7 billion (Q3 2025), and -$1.7 billion (Q2 2025) per Business Quant data.